Advertisement

Person › Details
Anker Lundemose (Mission Therapeutics Ltd.)
Lundemose, Anker (Mission Therapeutics 201501– CEO before Bionor Pharma + OSI Pharma + Prosidion + Novo Nordisk)
![]() |
Organisation | Mission Therapeutics Ltd. |
Former/major organisation | Bionor Pharma ASA | |
Group | Bionor Pharma (Group) | |
![]() |
Product | VACCINE, AIDS |
Product 2 | therapeutic vaccine | |
Record changed: 2024-07-04 |
Advertisement

More documents for Anker Lundemose
- [1] Mission Therapeutics Ltd.. (7/2/24). "Press Release: Mission Therapeutics Awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325". Cambridge....
- [2] Mission Therapeutics Ltd.. (3/21/24). "Press Release: Mission Therapeutics Commences Landmark Trial of MTX325, a Potential Disease-modifying Treatment for Parkinson’s Disease". Cambridge....
- [3] Mission Therapeutics Ltd.. (3/14/24). "Press Release: Mission Therapeutics Raises £25.2 Million to Progress Clinical Candidates in the Area of Mitophagy". Cambridge....
- [4] Mission Therapeutics Ltd.. (8/9/21). "Press Release: Mission and AbbVie Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Next Milestone- Mission Receives $20 Million Milestone payment". Cambridge....
- [5] Mission Therapeutics Ltd.. (7/6/20). "Press Release: Mission Raises $15m and Expands its Relationship with Pfizer". Cambridge....
- [6] Mission Therapeutics Ltd.. (5/1/19). "Press Release: Dr. James Summers Appointed to Mission Therapeutics’ Board of Directors". Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top